[ad_1]
Image source,fake images
Pfizer’s new corona vaccine reportedly has a 90% success rate
The co-developer of Pfizer’s new corona vaccine said that the new corona vaccine will start to play an important role next summer and people’s lives are expected to return to normal next winter.
Ugur Sahin, CEO of BioNTech, said the epidemic remains serious this winter because the vaccine will not play a major role any time soon.
In an interview with the BBC’s Andrew Marr Show, Sasin said he is confident that the vaccine can reduce the rate of infection among people and prevent the onset of symptoms of the new coronavirus disease.
He said the vaccine can cut the infection rate in half, which is already a huge contribution to the global epidemic.
“I am very confident that the person-to-person infection rate will be greatly reduced, maybe not 90%, but 50% possible. Let’s not forget that even 50% can effectively reduce the spread of the epidemic”.
Image source,Reuters
There are currently 11 new coronavirus disease vaccines in the world entering the final testing stage
The vaccine developed jointly by Pfizer and BioNTech last week became the world’s first effective vaccine. John Bell, a professor of medicine at the University of Oxford in the UK, once said that life can return to normal next spring.
But Sa Xin said it won’t be so soon. If all goes well, the vaccine is expected to be delivered “late this year, early next year.”
He said the goal is to ship 300 million doses globally by April next year, and this scale will only allow the vaccine to start working.
He said that after that, the role of vaccines will grow. “By next summer, the infection rate will drop. The most important thing is to increase the vaccination rate before next fall and winter.
The British government estimates that 10 million doses of vaccine will be obtained for the first batch of delivery by the end of the year and another 30 million doses will be ordered, which will be administered in three weeks and two stages.
Priority vaccines include the elderly and nursing home staff, followed by medical staff and the population over 80 years of age, and can then be vaccinated in batches in order of age.
Follow-up vaccination
Saxin said it’s unclear how long the vaccine can maintain the human body’s immunity, but he said if immunity drops significantly after a year, follow-up vaccine injections can be added, which isn’t a big deal.
He said the currently seen side effect of the vaccine is a few days of mild soreness at the vaccination site, and some trial participants will experience a mild fever for a few days after being vaccinated.
He said there were no other side effects or sequelae serious enough to stop or terminate the study.
Including the vaccines jointly developed by Pfizer and BioNTech, a total of 11 new vaccines against coronavirus disease worldwide have entered the final testing stage.
